Hear from our two AMP 2022 guest speakers about their experience utilising OGT’s SureSeq™ myeloid NGS research solutions in their genomic laboratories to detect key aberrations in myeloid malignancies, including CEBPA gene variants, FLT3-ITDS, and KMT2A-PTDs, among others.
Comparative analysis of testing methods used for the detection of internal tandem duplications (ITDs) in the KMT2A/MLL gene
Presented by José-Mario Capo-Chichi Ph.D., FCCMG, FACMG
Comparison of mutation profiles in MDS and AML: A single site experience
Presented by Elizabeth McCready Ph.D., FCCMG
SureSeq: For Research Use Only; Not for Use in Diagnostic Procedures.
